Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00742339

Recruitment Status : Terminated (Decision of independent monitoring committee: Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.)

First Posted : August 27, 2008

Last Update Posted : October 15, 2014

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by:

University of Padova

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	October 2013
Actual Study Completion Date :	October 2013

Publications:

Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007 Sep;56(9):1310-8. doi: 10.1136/gut.2006.107789. Epub 2007 Mar 27. No abstract available.

To Top